OCT 1 2 2004 W

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
053665-5010-01	09/844,201
A DRI ICANET	

APPLICANT

Louis S. KUCERA et al.

FILING DATE GROUP April 27, 2001 1623

U.S. PATENT DOCUMENTS

INITIAL	ļ <u>.</u>	DOCUMENT NUMBER	DATE	NAMENAME	CLASS	SUBCLASS	FILING DATE
110	A01	2,086,585	07/13/1937	Taub et al.	260	127	I ALTROPAIA
	A02	2,087,132	07/13/1937	Taub et al.	260	127	
	A03	2,108,765	02/15/1938	Domagk	167	30	
	A04	2,209,383	07/30/1940	Bock	8	116	
	A05	2,439,969	04/20/1948	Fourneau	260	338	
	A06	2,445,393	07/20/1948	Fourneau	260	338	
	A07	2,513,747	07/04/1950	Sallman et al.	260	338	
	A08	2,606,909	08/12/1952	Blicke	260	338	
	A09	2,689,790	09/21/1954	Mowry et al.	71	2.7	
	A10	2,950,253	08/23/1960	Kling et al.	252	152	
	Al1	3,054,678	09/18/1962	Michener et al.	99	150	
	A12	3,694,473	09/26/1972	Eibl et al.	260	403	
	A13	4,093,714	06/06/1978	Tolman et al.	424	180	
	A14	4,096,278	06/20/1978	Queuille	424	329	·
	A15	4,119,714	10/10/1978	Kny et al.	424	199	
	A16	4,159,988	07/03/1979	Eibl et al.	260	340.9R	
	A17	4,221,732	09/09/1980	Oette et al.	260	403	
	A18	4,235,877	11/25/1980	Fullerton		89	
	A19	4,291,024	09/22/1981	Turcotte	424	180	
	A20	4,329,302	05/11/1982	Hanahan et al.		925	
	A21	4,426,525		Hozumi et al.		22	
1	A22	4,444,766		Bosies et al.			
,	A23	4,471,113		MacCoss		211	
,	A24 '	4,540,521		Garst et al.	<u> </u>	29	
		4,619,917		Lee et al.		459	
 		4,622,392		Hong et al.		28.5	

EXAMINER

Ham Kens

DATE CONSIDERED

12-2-04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
053665-5010-01	09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE GROUP April 27, 2001

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	+	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
YO	A27		04/28/1987	Gordon et al.	514	397	
	A28	4,724,232	02/09/1988	Rideout et al.	514	50	
	A29	4,797,479	01/10/1989	Shuto et al.	536	28.5	
	A30	4,816,450	03/28/1989	Bell et al.	514	25	
	A31	4,826,823	05/02/1989	Cook et al.	514	46	
	A32	4,835,263	05/30/1989	Nguyen et al.	536	27	
	A33	4,837,023	06/06/1989	Eibl	424	439	
	A34	4,841,039	06/20/1989	Chu et al.	536	29	
	A35	4,880,782	11/14/1989	Eckstein et al.	514	45	
	A36	4,921,951	05/01/1990	Shuto et al.	536	28.5	
	A37	4,997,761	03/05/1991	Jett-Tilton	435	375	
	A38	5,026,687	6/25/1991	Yarchoan et al.	514	45	
	A39	5,034,394	07/23/1991	Daluge	514	261	
1	A40	5,138,045	08/11/1992	Cook et al.	536	27	
1	A41	5,221,696	06/22/1993	Ke et al.	514		<u> </u>
 		5,496,546	03/05/1996	Wang et al.		786	
		5,614,548	<u> </u>		424	78.36	
+			03/25/1997	Piantadosi et al.	514	440	
		5,633,388	05/27/1997	Diana et al.	548	305.7	
		5,770,584	06/23/1998	Kucera et al.	514	77	
	A46	5,830,905	11/03/1998	Diana et al.	514	322	
	A47	5,846,964	12/08/1998	Ozeki		182	
	A48	5,891,874	04/06/1999	Colacino et al.		234.5	
	A49	5,922,757	07/13/1999	Chojkier		458	-
	A50	5,962,437		Kucera et al.		77	
1, 1 		6,030,960		Morris-Natschke et al.	 '_	17	

EXAMINER

DATE CONSIDERED

12-2-04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-01 09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE GROUP April 27, 2001 1623

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY			r	
			<u> </u>	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
CO	B01	0 094 586	11/23/1983	EPO (English)			YES	NO
Ho	B02	0 109 255	05/23/1984	EPO (English)				
60	B03	0 142 333	05/22/1985	EPO (English)				
140	B04	0 145 303	06/19/1985	EPO (English)				
1/0	B05	0 146 258	06/26/1985	EPO (English)				
,	306	0 252 310	01/13/1988	EPO				
1/-		0 310 109				i		
140	B07	0 310 109	04/05/1989	EPO (English)				
40	B08	0 335 396	04/10/1989	EPO (English)				
Ho	B09	0 350 287	01/10/1990	EPO				
Ho	B10	0 348 859	01/03/1990	EPO (English)				
10	B11	0 416 401	03/13/1991	EPO				
10	B12	0 434 450	06/26/1991	EPO (English)				
	B13	0 506 704	07/11/1991	EPO				
No	B14	0 632 048	01/04/1995	EPO (English)				
	B15	1,561,630	03/28/1969	France -				
No	B16	199 14 474	10/07/1999	Germany (she to to				
No	B17	37 26 945 A1	02/23/1989	Germany (abstract only) Germany (abstract only)				
	B18	39 34 820 A1	04/25/1991	Germany (4077742) Sh vy)	_==			
40	B19	40 10 228 A1	10/02/1991	Germany (alos truct only)				
Ho	B20	2 239 243 A	06/26/1991	Great Britain				

EXAMINER Januar Cons	DATE CONSIDERED / 7 - 2	
	12-6	-0

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-01 09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE
April 27, 2001

GROUP 1623

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY CLASS SUBCL	100	TDANGE	
				CLASS SUBCL	135	TRANSL YES	NO
110	B21	42-13841	08/05/1967	Japan (ubstructorly)	_	163	NO
No	B22	61-238793	10/24/1986	Japan	•		
NO	B23	1029312	01/31/1989	Japan	_		
	B24	49-100224	09/21/1974	Japan			
AO	B25	08-268890	10/15/1996	Japan (abstract only)			
Ho	B26	10-101591	04/21/1998	Japan (abstract only)			
HO	B27	90/00555	01/25/1990	WIPO WIPO			
40	B28	90/05736	05/31/1990	WIPO (English)			
140	B29	90/15601	12/20/1990	WIPO (English)			
No	B30	91/05558	05/02/1991	WIPO	_		
40	B31	91/09602	07/11/1991	WIPO abstract only	\dashv		
Ho	B32	91/19726	12/26/1991	WIPO WIPO	\dashv		
HO	B33	91/18914	12/12/1991	WIPO (English)	-		
Ho.	B34	92/03462	03/05/1992	WIPO (abstract only)	\dashv		
HO	B35	92/06192	04/16/1992	WIPO (English)	-	+	-
110	B36	93/08807	05/13/1993	WIPO (English)	+		
to	B37	93/00910	01/21/1993	WIPO	-		
Ho	B38	93/16091	08/19/1993	WIPO	-		
#0	B39	93/16092	08/19/1993	WIPO (abstract only)	+		-
No	B40	93/17020	09/02/1993	WIPO (English)	-		-
1	B41	93/21191	10/28/1993	WIPO (English)	+		\dashv
\$6	B42	WO 94/28908	12/22/1994	WIPO	+		-
HO	B43	WO 98/22496	5/28/1998	WIPO (English)	+		
Hy	B44	WO 98/17679	4/30/1998	WIPO (English)	+		
#2	B45	WO 99/07734	2/18/1999	WIPO (English)	-		

EV.	MINE	-
LAA	IVIIIVE	. к

Hound Ca.

DATE CONSIDERED

12-2-04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
053665-5010-01	09/844,201
APPLICANT	
Lauis C VIICED A . 1	

Louis S. KUCERA et al.

FILING DATE GROUP April 27, 2001 1623

OTHER REFERENCES (Incl.	uding Author, Title,	e, Date, Pertinent Pages. E	tc.)
-------------------------	----------------------	-----------------------------	------

40	C01	Aggarwal, S. K. et al., "Synthesis and Biological Evaluation of Prodrugs of Zidovudine," J. Med. Chem., 33, 1505-10, 1990
	C02	Alt M. et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Potent and Specific Inhibitors of Hepatitis C Viral Translation," Archives of Virology 142:589-599, 1997
	C03	Alt M. et al., "Specific Inhibition of Hepatitis C Viral GeneExpression by Antisense Phosphorothioate Oligodeoxynucleotides," Hepatology 22:707-717. September 1995
	C04	Amari et al., "Isolation of Experimental Anti-AIDS Glycerophospholipids by Micro-Preparative Reversed-Phase High-Performance Liquid Chromatography," Journal of Chromatography, 590, 153-161, 1992
	C05	Anderson, L. J. et al., "Antigenic Characterization of Respiratory Syncytial Virus Strains with Monoclonal Antibodies," Journal of Infectious Diseases, 151:626-633, April 1985
	C06	Attwood, M. R. et al., "The Design and Synthesis of Potent Inhibitors of Hepatitis C Virus NS3-4A Proteinase," Antiviral Chemistry and Chemotherapy 10:259-273, September 1999
	C07	Berdel et al., "Cyto Toxicity of Thio Ether Lyso Phospho Lipids in Leukemias and Tumors of Human Origin," Cancer Research, Vol. 43, 5538-5543, 1983
	C08	Berenguer, M. et al., "Hepatitis C Virus in the Transplant Setting," Antiviral Therapy 3(Suppl. 3):125-136, 1998
	C09	Boldanova, N. B. et al., "Protective Effect of Phosphatidylcholine-Containing Liposomes in Experimental Toxic Hepatitis," Vopr. Med. Khim, 32, No. 3 (1986) Chemical Abstracts 105, p. 67, Abstract No. 35587k (1986)
	C10	72142p, 1991
	C11	Chen, "Design and Synthesis of Novel Nucleoside Analogs as Potential Antiviral Agents," Abstract American Assoc. of Pharmaceutical Scientists, Vol. 9, No. 10, 1992
	C12	Chu M. et al., "Isolation and Structure of SCH 351633: A Novel Hepatitis C Virus (HCV) NS3 Protease Inhibitor from the Fungus Penicillium Griseofulyum." Biographic and Medicinal Chemistry Letters 0.1040, 1052, 1000
	C13	Letters 37:7229-7232, 1996 Letters 37:7229-7232, 1996
	C14	Coe et al., "Preparation of Nucleotide Mimics with Potent Inhibitory Activity Against HIV Reserve Transcriptase," <u>J. Chem. Soc.</u> Perkin Trans 1, 3378-3379, 1991.
	C15	Crumpton, S. et al., "Novel Lipid Analogs with Cytostatic and Cytocidal Activity," Anticancer Research, Vol. 8, No. 6, pp. 1361-1366, NovDec. 1988
	C16	Daniel, L. W. et al., "Alkyl-Linked Diglygerides Inhibit Protein Kinase C Activation by Diacylglycerols," <u>Biochemical & Biophysical Research Communications</u> , 151, 291-97, Feb. 29, 1988
	C17	Dietzfelbinger, "Cytotoxic and Purging Effects of ET-18-OCH3 in Human Malignant Lymphoid Call Lines in View "
*HO	C18	Abstract 2472, Proceedings of the American Assoc. for Cancer Res., 31, 416, March 1990 Domawchowske J. B. et al., "Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis and Treatement," Clinical Microbiology Reviews, 12:298-309, April 1999

EXAMINER	Hours	
	Kuna	(Au

DATE CONSIDERED

12-2-04



(Use several sheets if necessary)

ATTY DOCKET NO. 053665-5010-01

APPLICATION NO 09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE
April 27, 2001

GROUP 1623

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

		gestive, Time, Pare, 1 ages, Lie.
Ho	C19	135:38-44, August 1999
	C20	Falsey A. R. et al., "Acute Respiratory Tract Infection in Daycare Centers for Older Persons," J Am Geriatric Soc., 43:30-36, 1995
	C21	Falsey A. R. et al., "Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings," J Am Geriatric Soc., 40:115-119, 1992
	C22	Fields, A. P. et al., "Human Immunodeficiency Virus Induces Phosphorylation of its Cell Surface Receptor," Nature, 333, 278-80, 19 May 1988
	C23	Galderisi U. et al., "Antisense Oligonucleotides as Therapeutic Agents," Journal of Cellular Physiology, 181:251-257, 1999
	C24	Glezen W. P. et al., "Risk of Primary Infection and Reinfection with Respiratory Syncytial Virus," Am J Dis Child, 140:543-546, 1986
	C25	Graham, F. L. et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5-DNA," Virology, Vol. 52, pp. 456-467, 1973
	C26	Guerguerian, A. et al., "Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis: a Randomized, Placebo-Controlled Trial," Am J Resp Crit Care Med., 160:829-834, 1999
	C27	Hall C. B. et al., "Infectivity of Respiratory Syncytial Virus by Various Routes of Inoculation," Infect Immun., 33:779-783, 1981
	C28	Hall, C. B. et al., "Nosocomial Respiratory Syncytial Virus Infections," N Engl J Med., 293:1343-1346, 1975
	C29	Hall C. B. et al., "Respiratory Syncytial Virus Infections Within Families," N Engl J Med, 294:414-419, 1976
	C30	Hancock et al., "Analogs of Natural Lipids. VII. Synthesis of Cyclopentanoid Analogs of Phosphatidylcholine," Journal of Lipid Research, Vol. 23, 183-189, 1982
	C31	Harada, S. et al., "Infection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay," Science, 229, 563-566, 9 Aug. 1985
	C32	Hayashi et al., "Antitumor Activity of a Novel Nucleotide Derivative, 5'-(1,2 Dipalmitoyl-sn-glycero-3-phospho)-5-fluorouridine (TJ14026) on Murine Tumors," Biol. Pharm. Bull., 16(8), 778-81, 1993
	C33	Henderson, F.W. et al., "Respiratory-Syncytial-Virus Infections, Reinfections, and Immunity: a Prospective, Longitudinal Study in Young Children," N Engl J Med., 300:530-534, 1979
4 Ho*	C34	Himmelmann, "Studies on the Cross Resistance Pattern of Membrane-Toxic Lipids in Vitro," Abstract 2448, Proceedings of the American Assoc. for Cancer Res., 31, 416, March 1990
		17. 17. 17. 17. 17. 17. 17. 17. 17. 17.

EXAMINER

Howard Deus

DATE CONSIDERED

12-2-01



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

ATTY DOCKET NO. 053665-5010-01

APPLICATION NO

09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE
April 27, 2001

GROUP 1623

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
Do	C35	Hirsch, M. S. et al., "Antiviral Agents," Fields Virology, Third Edition, Lippincott, Raven Publishers, page 431-466, 1996
HO	C36	Hostetler, et al., "Antiviral Activity of Phosphatidyl-Dideooxycytidine in Hepatitis B-infected Cells and Enhanced Hepatic Uptake in Mice," Antiviral Research, 59-65, 1994
HO	C37	Hostetler et al., "Phosphatidylazidothymidine and Phosphatidyl-ddC: Assessment of Uptake in Mouse Lymphoid Tissues and Antiviral Activities in Human Immunodeficiency Virus-Infected Cells and in Rauscher Leukemia Virus-Infected Mice," Antimicrobial Agents and Chemotherapy, Dec. 2702, 2707, 1004
40 40 40	C38	Pruska, J. F. et al., "In vivo Inhibition of Respiratory Syncytial Virus by Ribavirin," Antimicr Agents Chemother., 21:125-130, 1982
40	C39	Hsu, L. et al., "Synthesis of Anti-Restricted Pyrimidine Acyclic Nucleosides," <u>Journal of Organic Chemistry</u> , Vol. 57, No. 12, pp. 3354-3358, 1992
Ho	C40	IMPACT RSV Study Group, "Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-Risk Infants," Pediatrics, 102:531-537, 1998
	C41	4992 hot Submitted (6 vailable 62- reitage)
Ho	C42	Jayasuriya et al., Design, Synthesis, and Activity of Membrane-Disrupting Bolaphiles," <u>J. Am. Chem. Soc.</u> 112,
140	C43	Jia et al., "Diamide Analogues of Phosphatidylcholine as Potential Anti-AIDS Agents," J. Chem. Soc., 2521-2523, 1993.
HO	C44	Kakiuchi N. et al., "Non-peptide Inhibitors of HCV Serine Proteinase," J. FEBS Letters, 421:217-220, 1993
No	C45	Kasnar, B. et al., "Synthesis of 2',3'-Dideoxy- and 3'-Azido-2',3'Dideoxy-Pyridazine Nucleosides as Potential Agents," Nucleosides & Nucleotides, 13(1-3), pp. 459-479, 1994
HO HO HO	C46	Kawana, F. et al., "Inhibitory Effects of Antiviral Compounds on Respiratory Syncytial Virus Replication In Vitro," Antimicrob Agents Chemother., August 31, (8):1225-30, 1987
Ho	C47	Korba, B. E. et al., "Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Against Hepatitis B Virus Replication." Antiviral Research 19, 55, 70, 1992
#0		gp160/gp120 Binding to Monclonal Antibody." AIDS Research and Hymner Petersiana Cell Fusion and Surface
HO	(4)	Interaction with CD4 ⁺ Cells," Abstract 321, 32 nd Interscience Conf. on Antimicrobial Agents and Chemotherappy, Anaheim, 164, 11-14 Oct. 1992
HO	C50	Kucera, L. S., et al., "Activity of Triciribine and Triciribine-5'-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2k" Aids Research and Human Retroviruses, Vol. 9, No. 4, pp. 307-314, 1993

EXAMINER Leward Chus

DATE CONSIDERED

12-2-04



(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-01 09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE GROUP

	April 27, 2001 1623
C51	Kucera, "Effect of Membrane-Active Ether Lipid (EL) Analogues on Human Immunodeficiency Virus Production
 _	Two astronomy Flaque Assay, Annuals of the New York Academy of Sciences 545-548 26 Dec 1990
C52	Ruccra, Innibition of HIV-1 Plaque Formation by a Novel Class of Membrane-Active Ether Linid Analogo."
	international Conference on AIDS, Abstract No. W.C.O. 21 n 528 June 4-9 1989
C53	Kucera, "Inhibition of Human Immunodeficiency Virus-1 (HIV-1) by Novel Membrane Interactive Ether Linida."
	Abstract No. 2470, Proceedings of the American Assoc for Cancer Res. 31, 416, March 1000
C54	Rucera, L., et al., "Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-Mediated Call Fusion by
	1 Synthetic Phosphotipid Analogs, Antiviral Research, p. A260, 1985
C55	Kucera, "Investigations on Membrane Active Ether Lipid Analogs that Alter Functional Expression of UTV 1 1-4
1	Glycoproteins and Inhibit Pathogenesis," Abstract, Innovations in Therapy of Human Viral Diseases, Symposium,
	Research Triangle Park, 16, 6-9 Dec. 1992
C56	Kucera, L.S. et al., "In Vitro Evaluation and Characterization of Newly Designed Alkylamidophospholipid Analogues
	as Anni-riuman immunodenciency Virus Type I Agents." Antiviral Chemistry and Chemotherapy, 0:157, 165, 1009
C57	Kucera, L., et al., "Novel Ether Lipid Analogs of Platelet Activating Factor with Anti-Hepatitis B Virus Activity,"
<u> </u>	Abstract, ICAAC Orlando, 1994
C58	Kucera, L. et al., "Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and
	Induce Defective Virus Formation," AIDS Research And Human Retroviruses, 6, 491-501, 1990
C59	Kumar, R., et al., "Equal Inhibition of HIV Replication by Steroisomers of Phosphatidyl- Azidothymidine Look of
ļ	Steleospecificity of Lysosomal Phospholipase A. The Journal of Riological Chemistry, 267, 2029, 2020, 1002
C60	Lister et al., "Cyclopentanoid Analogs of Phosphatidylcholine: Susceptibility to Phospholipase A2," Journal of Lipid
L	[KCSCAICH, VOI, 29, 1297-1308, 1988
C61	Maccjak, D. J. et al., "Inhibition of Viral Replication by Nuclease Resistant Hammerhead Birozymes Directed Against
	riepatitis C virus Riva, riepatology, 30 Abstract 995, 1999
C62	M. MacCoss et al., "Synthesis and Biological Activity of Novel Nucleoside-Phospholipid Prodrugs," 4th International
	Round Table Nucleosides, Nucleotides and their Biological Applications, Antwerp, February 4-6, p. 255-263
	1 columny 4-0, 1961
C63	Marasco, Jr., C. J., "The Synthesis and Biological Activity of Novel Alkylglycerol Derivatives as Inhibitors of Protein
	Remade C Activity, Neoplastic Cell Growin, and HIV-1 Infectivity." Dissertation for Ph D. Univ. of No. Carolina
	<u>Chapet 11111, 1990</u>
C64	Marasco, C. J. et al., "Synthesis and Biological Activity of Novel Quaternary Ammonium Derivatives of
	Alkylglycerols as Potent Inhibitors of Protein Kincase C." Journal of Medicinal Chemistry, No. 33, pp. 985, 992
	Wilden 1990
C65	Marasco et al., "The Synthesis and Biological Testing of Alkyl Glycerols as Potential Inhibitors of Protein Kinase C,"
	American Assoc. of Pharmaceutical Scientists Abstract, Vol. 9, No. 10, 1992
	C52 C53 C54 C55 C56 C57 C58 C59 C60 C61 C62

EX.				~ ~~
P. X.	ΔΛ	<i>7</i> 8 II 8	v	ď

Haml Cles

DATE CONSIDERED

12-2-04



(Use several sheets if necessary)

APPLICATION NO		
09/844,201		
APPLICANT		
Louis S. KUCERA et al.		
	09/844,201	

GROUP

1623

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

FILING DATE

April 27, 2001

		THER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
#0	C66	Marx, M. H. et al., "Synthesis and Evaluation of Neoplastic Cell Growth Inhibition of 1-N-Alkylamide Analogues of Glycero-3-Phosphocholine," <u>Journal of Medicinal Chemistry</u> , <u>Abstract</u> , 31, 858-863, March 28, 1988
40	C67	Meert, K. L. et al., "Aerosolized Ribavirin in Mechanically Ventilated Children with Respiratory Syncytial Virus Lower Respiratory Tract Disease: a Prospective Double-Blind Randomized Trial," Crit Care Med., Abstract 22:566-572, April 1994
Ho	C68	Mertes et al., "Charge-Spatial Models. cis- and trans-3- and -4- Substituted Cyclohexyl Phosphates as Analogs of 2'- Deoxyuridine 5'-Phosphate," J. Med. Chem., Vol. 12(5), 828-832, 1968
40	C69	Meyer, K. L., et al., "In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents," J. Med. Chem, 34, 1377-1383, 1991
Ho	C70	Meyer, "Synthesis and Evaluation of Anti-HIV-1 Ether Lipids," AAPS Meeting, Atlanta Abstract N. MN-510, p. S-41, 22-25 Oct. 1989
40	C71	Miller, R. H., et al., "Common Evolutionary Origin of Hepatitis B Virus and Retroviruses," Proc. Natl. Acad. Sci. USA, 83, pp. 2531-2535, April 1986
X10	C72	Mitsuya, H. et al., "Strategies for Antiviral Therapy in AIDS," Nature, 325, 773-78, 26 February 1987
#0 #0 #0	C73	Modest, "Combination Chemotherapy Studies with Antitumor and Antiviral Ether Lipid Analogs," Abstract 2471, Proceedings of the American Assoc. for Cancer Res., 31, 416 Abstract 2471, March 1990
Ho	C74	Modest, E., et al., "Comparison of Cell Kill Induced by Two Ether Lipids in Combination with Hyperthermia," Proceedings of the American Association for Cancer Research; Preclinical Pharmacology Experimental Therapeutics, Vol. 31, pp. 416, Abstract 2467, March 1990
Ho,	C75	Modest, E. J. et al., "Pharmacological Effects and Anticancer Activity of New Ether Phospholipid Analogs," The Pharmacological Effect of Lipids III: Role of Lipids in Cancer Research, (IN PRESS), pp. 330-337, 1989
40	C76	Molla, A. et al., "Human Serum Attenuates the Activity of Protease Inhibitors Toward Wild-Type and Mutuant Human Immunodeficiency Virus," Virology, 250:255-262, 1998
Ho	C77	Morrey, J. D. et al., "Effects of Zidovudine on Friend Virus Complex Infection in Rfv-3" Genotype-Containing Mice Used as a Model for HIV Infection," Journal of Acquired Immune Deficiency Syndromes 3, 500-10, 1990
Ho	C78	Morris-Natschke, S. L. et al., "Synthesis of Phosphocholine and Quaternary Amine Ether Lipids and Evaluation of in Vitro Antineoplastic Activity," J. Med. Chem., 36:2018-2025, 1993
40	C79	Morris-Natschke, S. et al. "Synthesis of Sulfur Analogues of Alkyl Lysophospholipid and Neoplastic Cell Growth Inhibitory Properties," J. of Med. Chem., 29, 2114-17, 1986
#/0	C80	Mutson, M. A. et al., "Two Distinct Subtypes of Human Respiratory Syncytial Virus," The Journal of General Virology, 66:2111-2124, October 1985 Auchon Mufson, M.A. et al.
Ho	C81	Nara, P. L. et al., "Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human Immunodeficiency Virus Neutralizing Antibody," AIDS Research and Human Retroviruses, 3, 283-302, 1987
Ho	C82	Noseda, A. et al., "In Vitro Antiproliferative Activity of Combinations of Ether Lipid Analogues and DNA-interactive Agents Against Human Tumor Cells," Cancer Research, 48, 1788-1791, April 1, 1988

EXAMINER	1/ .	
	X forms	K /m

DATE CONSIDERED

12-2-04

			ATTY DOCKET NO.	APPLICATION NO		
			053665-5010-01	09/844,201		
LIST OF R	EFER	ENCES CITED BY APPLICANT	APPLICANT			
		(Use several sheets if necessary)	Louis S. KUCERA et al.			
			FILING DATE	GROUP		
			April 27, 2001	1623		
•		OTHER REFERENCES (Including Auth		Etc.)		
· +/1	C83	Noseda, A. et al., "Neoplastic Cell Inhibition with I	New Ether Lipids Analogs," <u>Lipids</u> , 2	2, 878-883, Nov. 1987		
1	C84	Ostertag, W. et al., "Induction of Endogenous Viru. Transformed by Friend Virus," Proc. Nat. Acad. Sc	s and of Thymidine Kinase by Bromo i. USA, 71, 4980-85, Dec. 1974	deoxyuridine in Cell Cultures		
	C85	Pacheco, D. Y. et al., "Mechanisms of Toxicity of I	Hepsulfam in Human Tumor Cell Lin er Research, 81, 412, May 1990			
	C86	Painuly et al., "Preparative HPLC of an Experimen	tal Anti-HIV Analogue of AZT: Azi romatography, 16(11), 2237-2248, 19	93		
	C87	Pajouhesh et al., "Synthesis of Polar Head Group Head Phosphatidyl-N, N-Dimethylethanolamine, and N-Dimethylet	Iomologs of All-trans-cyclopentano-posphatidylethanolamine," <u>Journal of I</u>	hosphatidylcholine, <u>lipid Research</u> , Vol. 25, 294-		
	C88	Piantadosi, C. et al., "Synthesis and Evaluation of I				
	C89	Pidgeon, C. et al., "Anti-HIV Drugs Conjugated to				
	C90	Pidgeon C. et al., "Novel Acylated Phospholipid D				
	C91	The PREVENT Study Group, "Reduction of Respirate Infants with Bronchopulmonary Dysplasia Using Res 99:93-99, 1997	piratory Syncytial Virus Immune Globu	llir: Prophylaxis, Pediatrics,		
	C92	Prince, G. A., "The Pathogenesis of Respiratory Sync				
	C93	Qasim M.A. et al. "Interscaffolding Additivity. Association with Serine Proteinases.", Biochemistry 36:1.	598-1607, 1997			
	C94	Qiu et al., "Membrane Properties of Antiviral Phos Biochemistry, 33(4), 960-72, 1994	pholipids Containing Heteroatoms in			
	C95	C. Raetz et al., "Phospholipid Derivative of Cytosin				
	C96	Rodriguez, W. J. et al., "Prospective Follow-Up an Trial of Ribavirin Therapy in Respiratory Syncytia May 1999	l Virus Bronchiolitis," Arch Pediatr A	dolesc Med, 153:469-474,		
	C97	Runge et al., "Destruction of Human solid Tumors Institute, Vol. 64, 1301-1306, 1980	by Alkyl Lyso Phospho Lipids," Jour	nal of the National Cancer		
-	C98	Sable, C. A. et al., "Orthomyxoviral and Paramyxo Abstract, 9:987-1003, December 1995	viral Infections in Transplant Patients	," Infect Dis Clin North Am,		
	C99	Sarin, P. S. et al., "Effects of a Novel Compound (a Journal of Medicine, Vol. 313, 1289-90, Nov. 14, 1		itro," The New England		
	C100	Scolaro M. J. et al., "Inhibition of Virus Replication	n with Oligonucleotides," Chemical A	Abstracts, 117:124476, 1992		
	C101	Sidoti et al., "Cytostatic Activity of New Synthetic				
*Ho	C102	717, 1992 Small, "Characterization of Cells Sensitive and Re- American Assoc. for Cancer Res., 31, 416, March		7. Proceedings of the		
110	1	American Assoc. for Cancer Res., 31,446, March				
EXAMINER	×	bund Cles	DATE CONSIDERED 12-	2-04		
*EXAMINER:	Initial if	reference considered, whether or not citation is in conformand	ce with MPEP 609; Draw line through citati	on if not in conformance and not		
considered. Inc	lude cop	y of this form with next communication to applicant.				



NCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO 053665-5010-01 09/844,201

APPLICANT

Louis S. KUCERA et al.

FILING DATE GROUP
April 27, 2001 1623

t		April 27, 2001 1023
to	C103	Smith, D. W. et al., "A Controlled Trial of Aerosolized Ribavirin in Infants Receiving Mechanical Ventilation for Severe Respiratory Syncytial Virus Infection," New England Journal of Medicine, 325:24-29, July 1991
	GIOA	Steim et al., "Lipid Conjugates of Antiretroviral Agents. I. Azidothymidine-Monophosphate-Digylceride: Anti-HIV
11	C104	Activity, Physical Properties, and Interaction with Plasma Proteins," Biochemical and Biophysical Research
Alo	1	Communications, Vol. 171, No. 1, 451-457, 1990
1		Sudo K. et al, "Inhibitory Effects of Podphyllotoxin Derivatives on Herpes Simplex Virus Replication;" Antiviral Chemistry
Ho	C105	and Chemotherapy 9:186, 1998
	 	Sudo K. et al., "Establishment of an In Vitro System for Screening Hepatitis C Virus Protease Inhibitors Using High
40	C106	Performance Liquid Chromatography," Antiviral Research 32:9-18, 1996
		Sunamoto, J. et al., "Induction of Cytotoxic T Cell," Chemical Abstracts, 117:68365, 1992
10	C107	
Ho Ho	C108	Surles, J. R. et al, "Multigram Synthesis of 1-Alkylamido Phospholipids," Lipids, 28, 55-57, 1993
-17	C109	Swayze, E. E., et al., "Synthesis of 1-(2-Aminopropyl) Benzimidazoles, Structurally Related to the Tibo Derivative
1 1/2	(0.0)	R82150, With Activity Against Human Immunodeficiency Virus,"
1 100	ŀ	Biographic & Medical Chemistry Letters, Vol. 3, No. 4, pp 543-546, 1993
//	C110	Takeshita N. et al., "An Enzyme-Linked Immunosorbent Assay for Detecting Proteolytic Activity of Hepatitis C Virus
Ao	CITO	Proteinase," Analytical Biochemistry 247:242-246, May 1, 1997
HO	C111	Tarnowski et al., "Effect of Lyso Lecithin and Analogs on Mouse Ascites," Cancer Research, Vol. 38, 339-344, 1978
1,1	C112	Thompson, J., et al., "Phospholipid Analog Inhibition of Human Immunodeficiency Virus Envelope Glycoprotein-
40	C112	Mediated Cell Fusion," Abstracts of the 2nd National Conference on Human Retroviruses, Session 18, 1995
#10	C113	Tiollais, P., et al., "Hepatitis B. Virus," Scientific American, 116-123, April 1991
10	6114	Van Wijk et al., "Synthesis and Antiviral Activity of 3'-azido-3'deoxythymidine Triphosphate Distearoylglycerol: A
410 Ho	C114	Novel: Phospholipid Conjugate of the Anti-HIV Agent AZT," Chemistry and Physics of Lipids, 70, 213-222, 1994
		Van Wijk, G. M. et al., "Spontaneous and Protein-Mediated Intermembrance Transfer of the Antiretroviral
10	C115	Liponucleotide 3'-Deoxythymidine Diphosphate Diglyceride," <u>Biochemistry</u> , 31, 5912-5917, June 30, 1992
//	 	Vos, G. D. et al., "Treatment of Respiratory Failure Due to Respiratory Syncytial Virus Pneumonia with Natural
170	C116	Conference " Dedicte Delegand Abstract 20:412, 415. December 1906
1	↓	Surfactant," Pediatr Pulmonol., Abstract 22:412-415, December 1996 Wang, E. E. et al., "Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Prospective
H2	C117	wang, E. E. et al., remaind investigators Conabonative network on intertuous in Canada (Fichica) i tospective
1 11/2	}	Study of Risk Factors and Outcomes in Patients Hospitalized with Respiratory Syncytial Viral Lower Respiratory
· · · · · · · · · · · · · · · · · · ·	 	Tract Infection," Abstract, J Pediatr, 126:212-219, February 1995
Ho Ho	C118	Whimbey, E. et al., "Community Respiratory Virus Infections Among Hospitalized Adult Bone Marrow Transplant
M	<u> </u>	Recipients," Abstract, Clin Infect Dis., 22:778-782, May 1996
172	C119	Yamaue, H. et al., "Chemosensitivity Testing with Highly Purified Fresh Human Tumor Cells with the MTT
1		Colorimetric Assay," Abstract, Eur J Cancer, 27:1258-1263, 1991
1/2	C120	Yanagawa, H. et al. "Spontaneous Formation of Superhelical Strands," Journal of the American Chemical Society,
NO	3.20	111, 4567-70, June 21, 1989
1	C121	Yarchoan, R. et al., "Therapeutic Strategies in the Treatment of AIDS," Annual Reports in Medicinal Chemistry, Vol.
HD	1 (12)	23, 253-263, 1988

EXAMINER Howal 12-2-04